Nevro Corp is a medical device company ... a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.

a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States. Unraveling the Financial Story of Nevro Market Capitalization Analysis ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its neuromodulation platforms for treating chronic pain. The all-cash deal comes ...

Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 results ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Nevro (NVRO) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...

The company started 2025 on a solid note, driven by a decent guidance for the year, but a deal for loss-making Nevro creates some discomfort among investors. All this makes me intrigued to watch ...

In a report released on February 7, Nathan Treybeck from Wells Fargo maintained a Hold rating on Nevro Corp (NVRO – Research Report), with a price target of $5.85. The company’s shares closed ...

Fintel reports that on February 7, 2025, Piper Sandler upgraded their outlook for Nevro (NYSE:NVRO) from Underweight to Neutral. As of January 28, 2025, the average one-year price target for Nevro ...

Jefferies upgraded Nevro (NVRO) to Hold from Underperform with a price target of $5.85, up from $4.50, after the company entered into a definitive agreement for Globus Medical to acquire all its ...